299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details
臨床試験数 : 1,696 / 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02163681 (ClinicalTrials.gov) | January 1, 2011 | 10/6/2014 | MRI as a Means to Measure Lung Function: Non-Invasive Imaging in Neonates and Children | Healthy;Cystic Fibrosis (CF);Asthma;Bronchopulmonary Dysplasia (BPD) | Drug: Hyperpolarized Helium-3 MRI of the chest | University of Virginia | Xemed LLC | Completed | 4 Months | 65 Years | All | 77 | N/A | United States | |
| 2 | NCT01161537 (ClinicalTrials.gov) | October 2010 | 9/7/2010 | Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation | A Phase 2, Single-Blind, Placebo-Controlled Study to Evaluate the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis, the G551D Mutation, and FEV1 =40% Predicted | Cystic Fibrosis | Drug: VX-770;Drug: Placebo | Vertex Pharmaceuticals Incorporated | Cystic Fibrosis Foundation Therapeutics | Completed | 12 Years | N/A | All | 13 | Phase 2 | United States |
| 3 | NCT00846573 (ClinicalTrials.gov) | November 2008 | 16/2/2009 | Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders | Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders | COPD;Cystic Fibrosis;Asthma;Healthy | Drug: Hyperpolarized Helium-3 | University of Massachusetts, Worcester | NULL | Terminated | 5 Years | N/A | All | 14 | N/A | United States |
| 4 | EUCTR2017-000672-28-Outside-EU/EEA (EUCTR) | 27/03/2017 | Study of the Effect of VX-770 on Hyperpolarized Helium-3 MagneticResonance Imaging in Subjects With Cystic Fibrosis and the G551DMutation | A Phase 2, Single-Blind, Placebo-Controlled Study to Evaluate the Effectof VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging inSubjects With Cystic Fibrosis, the G551D Mutation, and FEV1 =40%Predicted | cystic fibrosis MedDRA version: 19.1;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Kalydeco Product Name: ivacaftor Product Code: VX-770 INN or Proposed INN: IVACAFTOR | Vertex Pharmaceuticals Incorporated | NULL | NA | Female: yes Male: yes | 17 | Phase 2 | United States |